Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

Trial Profile

Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs NDV 3 (Primary) ; Aluminium hydroxide
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions
  • Sponsors NovaDigm Therapeutics
  • Most Recent Events

    • 25 Apr 2018 Results presented in a NovaDigm Therapeutics Media Release.
    • 25 Apr 2018 According to a NovaDigm Therapeutics media release, Paul Nyirjesy Professor of Obstetrics and Gynecology and of Medicine at Drexel University College of Medicine, is the principal investigator of this study.
    • 25 Apr 2018 Results of post hoc exploratory analysis evaluating an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of Recurrent Vulvovaginal Candidiasis published in the Clinical Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top